Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS

Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS

Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) is the most effective therapy for complications of portal hypertension. However, clinical outcomes following TIPS placement vary widely between patients and identifying ideal candidates remains a challenge. Soluble uroki...

Full description

Bibliographic Details
Main Authors:	Sven H. Loosen, Fabian Benz, Raphael Mohr, Philipp A. Reuken, Theresa H. Wirtz, Lioba Junker, Christian Jansen, Carsten Meyer, Michael Praktiknjo, Alexander Wree, Johanna Reißing, Münevver Demir, Wenyi Gu, Mihael Vucur, Robert Schierwagen, Andreas Stallmach, Anselm Kunstein, Johannes Bode, Christian Trautwein, Frank Tacke, Tom Luedde, Tony Bruns, Jonel Trebicka, Christoph Roderburg
Format:	Article
Language:	English
Published:	Elsevier 2024-05-01
Series:	JHEP Reports
Subjects:	suPAR TIPS portal hypertension survival biomarker
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555924000557

Similar Items

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis.
by: Fabian Benz, et al.
Published: (2020-01-01)

Evaluation of soluble urokinase-type plasminogen activator receptor (suPAR) quick test for triage in the emergency department
by: Pratyush Kumar, et al.
Published: (2019-01-01)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
by: Mohamed Abd‑Ellatif El‑Patal, et al.
Published: (2022-10-01)

Prospective use of soluble urokinase plasminogen activator receptor to screen TB co-infected with HIV patient among TB patient
by: Tri Yudani Mardining Raras, et al.
Published: (2017-10-01)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
by: Dimitrios Velissaris, et al.
Published: (2022-09-01)

Soluble urokinase-type plasminogen activator receptor (suPAR) – a possible biomarker for bacteremia in sepsis / Forma solubilă a receptorului pentru activatorul de plasminogen de tip urokinază (suPAR) – un biomarker posibil pentru bacteriemie în sepsis
by: Georgescu Anca-Meda, et al.
Published: (2015-03-01)

The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
by: Kristian Blomberg, et al.
Published: (2021-10-01)

Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure
by: Yunyun Wang, et al.
Published: (2021-11-01)

Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma
by: Niemelä T, et al.
Published: (2022-05-01)

Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis
by: Wenjuan Wu, et al.
Published: (2018-05-01)

Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection
by: Sebastian M. Klim, et al.
Published: (2024-02-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
by: Mariangela Manfredi, et al.
Published: (2023-04-01)

Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction
by: Nils A. Sörensen, et al.
Published: (2019-03-01)

Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
by: Alice G. Vassiliou, et al.
Published: (2022-05-01)

Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis
by: Jing-jing Zhao, et al.
Published: (2018-05-01)

Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
by: Ioannis Griveas, et al.
Published: (2021-07-01)

Correlation between soluble urokinase plasminogen activator receptor with CD4 T lymphocyte and WHO clinical staging of HIV infection
by: Shinta Oktya Wardhani, et al.
Published: (2010-04-01)

Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
by: Filomena Napolitano, et al.
Published: (2021-10-01)

The predictive value of modified soluble urokinase plasminogen activator receptor (suPAR) with National Early Warning Score (NEWS) for mortality in emergency elderly patients in Japan: a prospective pilot study
by: Toshiya Mitsunaga, et al.
Published: (2023-01-01)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
by: Anurag Mehta, et al.
Published: (2020-03-01)

Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis
by: Hidi A. A. Abdellatif, et al.
Published: (2023-04-01)

Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes
by: Tom Luedde, et al.
Published: (2021-08-01)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
by: Viktor Rotbain Curovic, et al.
Published: (2022-04-01)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
by: Charlotte Höybye, et al.
Published: (2019-05-01)

Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke
by: Dorota Różański, et al.
Published: (2021-12-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
by: Burcin Özdirik, et al.
Published: (2020-05-01)

Ability of combined soluble urokinase plasminogen activator receptor to predict preventable emergency attendance in older patients in Japan: a prospective pilot study
by: Toshiya Mitsunaga, et al.
Published: (2022-11-01)

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-04-01)

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis
by: Jinjin Ma, et al.
Published: (2023-04-01)

Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer
by: Yalcin Selim, et al.
Published: (2020-07-01)

Evaluation of suPAR Levels in Attention Deficit Hyperactivity Disorder Etiopathogenesis
by: Ayşe Irmak, et al.
Published: (2019-03-01)

Evaluation of sTREM1 and suPAR Biomarkers as Diagnostic and Prognostic Predictors in Sepsis Patients
by: Nasr El-Din A, et al.
Published: (2021-08-01)

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trialResearch in context
by: Karolina Akinosoglou, et al.
Published: (2023-02-01)

Variability in CKD Biomarker Studies: Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Kidney Disease Progression in the Chronic Kidney Disease in Children (CKiD) StudyPlain-Language Summary
by: Alison G. Abraham, et al.
Published: (2021-09-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

Circulating microRNA-150 serum levels predict survival in patients with critical illness and sepsis.
by: Christoph Roderburg, et al.
Published: (2013-01-01)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
by: Jan Simon Scharrenberg, et al.
Published: (2019-11-01)

Diagnostic and Prognostic Values of Serum C-reactive Protein, Procalcitonin, Soluble Urokinase Plasminogen Activator Receptor, and Neopterin Levels in Hospitalized Patients in the Intensive Care Unit with Ventilator-associated Pneumonia
by: Reyhan ÖZTÜRK, et al.
Published: (2021-12-01)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
by: Evangelos Terpos, et al.
Published: (2020-10-01)

Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer
by: Sven H. Loosen, et al.
Published: (2020-04-01)